Clinically stable treatment-experienced adults receiving tenofovir and didanosine

HIV Clinical Trials

Volumn 7, Issue 1, 2006, Pages 10-15

  Di Biagio, Antonio ^a   Beltrame, Andrea ^a   Cenderello, Giovanni ^b   Ferrea, Giuseppe ^b   De Maria, Andrea ^a,c  

^a UNIVERSITY OF GENOA   (Italy)

^b ASL 1 Imperiese   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Drug experienced; HIV 1; Tenofovir

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DRUG SUBSTITUTION; EXPERIENCE; FEAR; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LYMPHOCYTE COUNT; MALE; NEPHROTOXICITY; PANCREAS DISEASE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIROLOGY;

ADENINE; ADULT; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DRUG THERAPY, COMBINATION; FEMALE; HIV; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; STATISTICS, NONPARAMETRIC; STAVUDINE;

EID: 33646568447     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/0B0R-J1LP-KQPF-43HB     Document Type: Article

References (14)

1. Maggiolo F, Ripamonti D, Arici C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials. 2002;3(5):371-378.
2. Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA),Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother. 1998;42(3):612-617.
3. Lyseng-Williamson KA, Reynolds NA, Plosker GL. Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection. Drugs. 2005;65(3):413-432.
4. Anderson PL. Pharmacologic perspectives for once-daily antiretroviral therapy. Ann Pharmacother. 2004;38(11): 1924-1934. Epub 2004 Oct 12.
5. Gallant JE, Staszewski S, Pozniak AL, et al., 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191-201.
6. Kearney BP, Isaacson E, Sayre J, et al. Didanosine and tenofovir DF drug-drug interactions: assessment of didanosine dose reduction. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston MA. Abstract 533.
7. Ray AS, Olson L, Fridland A. Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother, 2004;48(4):1089-1095.
8. Negredo E, Molto J, Burger D, et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS. 2004; 18(3):459-463.
9. Leon A, Martinez E, Mallolas J, Laguno M, Blanco JL, Pumarola T, Gatell JM. Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine. AIDS. 2005;19(2):213-215.
10. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003 5;36(8):1070-1073. Epub 2003 Apr 4.
11. Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS. 2005;19(1):93-95.
12. Martinez E, Milinkovic A, de Lazzari E, et al. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults. Lancet. 2004;364(9428):65-67.
13. Barrios A, Rendon A, Negredo E, et al. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS. 2005;19(6):569-575.
14. Karrer U, Ledergerber B, Furrer H, et al., Swiss HIV Cohort Study. Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. AIDS. 2005;19(17):1987-1994.